Table 2.
DMGs most likely involved in female prolificacy pathways
| Gene Name | DMR | GO pathway | GO ID | KEGG Pathway | KO ID | ||
|---|---|---|---|---|---|---|---|
| location in chr | meth diff (LP vs HP) | P-value | |||||
| BMP7 | 13(58222103–58,222,185) | −0.243 | 4.71E-08 | menstrual cycle phase | GO:0022601 | TGF-beta signaling pathway | ko04350 |
| 13(58258207–58,258,215) | 0.203 | 8.29E-06 | Hippo signaling pathway | ko04390 | |||
| 13(58174539–58,174,596) | 0.218 | 0.000243 | Cytokine-cytokine receptor interaction | ko04060 | |||
| 13(58235661–58,235,840) | 0.344 | 3.01E-06 | |||||
| BMPR1B | 6(29427102–29,427,372) | −0.232 | 7.32E-05 | ovarian cumulus expansion | GO:0001550 | TGF-beta signaling pathway | ko04350 |
| 6(29490707–29,490,892) | 0.227 | 0.000308 | Hippo signaling pathway | ko04390 | |||
| 6(29297691–29,297,945) | 0.266 | 6.21E-06 | Cytokine-cytokine receptor interaction | ko04060 | |||
| CTNNB1 | 19(14002501–14,002,561) | −0.541 | 2.32E-10 | oocyte development | GO:0048599 | Hippo signaling pathway | ko04390 |
| 19(14008957–14,009,244) | −0.442 | 9.27E-14 | Adherens junction | ko04520 | |||
| 19(13978757–13,978,906) | −0.424 | 4.50E-20 | Tight junction | ko04530 | |||
| 19(13870396–13,870,492) | −0.409 | 9.06E-11 | Leukocyte transendothelial migration | ko04670 | |||
| 19(13826519–13,826,590) | −0.333 | 3.17E-10 | |||||
| 19(13831621–13,831,667) | −0.322 | 1.81E-11 | |||||
| 19(14018620–14,018,858) | −0.313 | 3.71E-07 | |||||
| 19(13959030–13,959,259) | −0.308 | 2.10E-14 | |||||
| 19(13989628–13,989,661) | −0.282 | 1.63E-06 | |||||
| 19(13882120–13,882,179) | −0.275 | 8.06E-08 | |||||
| 19(13959905–13,959,997) | −0.271 | 0.00168 | |||||
| 19(13993527–13,994,032) | −0.243 | 5.13E-11 | |||||
| 19(13685445–13,685,483) | −0.231 | 7.72E-05 | |||||
| 19(13675322–13,675,759) | 0.207 | 7.68E-07 | |||||
| 19(13676205–13,676,451) | 0.209 | 1.74E-05 | |||||
| 19(13706582–13,706,880) | 0.233 | 8.69E-07 | |||||
| 19(13853573–13,853,684) | 0.277 | 1.04E-07 | |||||
| 19(13793737–13,793,755) | 0.319 | 0.000111 | |||||
| 19(13707639–13,707,973) | 0.344 | 3.25E-07 | |||||
| 19(13682987–13,683,047) | 0.404 | 4.49E-08 | |||||
| 19(13815477–13,815,573) | 0.418 | 1.70E-06 | |||||
| 19(13708400–13,708,447) | 0.617 | 2.94E-26 | |||||
| FSHR | 3(75192698–75,192,705) | −0.371 | 2.39E-05 | primary ovarian follicle growth | GO:0001545 | cAMP signaling pathway | ko04024 |
| 3(75379496–75,379,558) | −0.365 | 1.81E-08 | Neuroactive ligand-receptor interaction | ko04080 | |||
| 3(74644092–74,644,099) | 0.154 | 8.92E-05 | |||||
| 3(74716438–74,716,537) | 0.213 | 9.40E-06 | |||||
| 3(75040358–75,040,859) | 0.218 | 9.66E-07 | |||||
| 3(75387483–75,387,659) | 0.224 | 0.000138 | |||||
| 3(75366395–75,366,601) | 0.226 | 5.29E-05 | |||||
| 3(75298678–75,298,880) | 0.249 | 3.49E-09 | |||||
| 3(75134625–75,134,944) | 0.257 | 6.08E-07 | |||||
| 3(74739631–74,739,782) | 0.352 | 3.21E-08 | |||||
| 3(75132060–75,132,090) | 0.402 | 9.62E-11 | |||||
| 3(75027605–75,027,609) | 0.466 | 1.72E-08 | |||||
| 3(75289648–75,289,665) | 0.483 | 2.63E-09 | |||||
| 3(75291188–75,291,243) | 0.625 | 9.79E-18 | |||||
| FST | 16(25647868–25,647,877) | −0.291 | 2.30E-06 | female gonad development | GO:0008585 | TGF-beta signaling pathway | ko04350 |
| LHCGR | 3(75688216–75,688,347) | −0.286 | 1.48E-05 | ovarian follicle development | GO:0001541 | Neuroactive ligand-receptor interaction | ko04080 |
| 3(75736243–75,736,624) | −0.214 | 1.87E-07 | |||||
| 3(75712912–75,712,941) | 0.209 | 0.00544 | |||||
| TGFB2 | 12(20040207–20,040,350) | 0.229 | 5.70E-08 | menstrual cycle phase | GO:0022601 | Cytokine-cytokine receptor interaction | ko04060 |
| 12(20044759–20,045,177) | 0.23 | 2.80E-05 | FoxO signaling pathway | ko04068 | |||
| 12(20286676–20,286,930) | 0.245 | 0.000418 | TGF-beta signaling pathway | ko04350 | |||
| 12(20300287–20,300,401) | 0.316 | 1.90E-06 | Hippo signaling pathway | ko04390 | |||
| 12(19982100–19,982,518) | 0.206 | 4.89E-09 | |||||
| 12(19995176–19,995,216) | 0.243 | 5.97E-07 | |||||
| 12(20020000–20,020,214) | 0.278 | 8.20E-11 | |||||
| TGFB3 | 7(84205818–84,206,098) | −0.205 | 0.000768 | menstrual cycle phase | GO:0022601 | Cytokine-cytokine receptor interaction | ko04060 |
| 7(84097027–84,097,093) | 0.217 | 0.000423 | FoxO signaling pathway | ko04068 | |||
| 7(84139476–84,139,762) | 0.227 | 8.22E-06 | TGF-beta signaling pathway | ko04350 | |||
| 7(84057073–84,057,143) | 0.24 | 4.51E-05 | Hippo signaling pathway | ko04390 | |||
| 7(84105957–84,106,089) | 0.262 | 0.000133 | |||||
| INHBA | 4:79,346,323–79,346,467 | 0.281 | 7.62E-06 | ovarian follicle development | GO:0001541 | TGF-beta signaling pathway | ko04350 |
| 4:79,358,172–79,358,309 | 0.2 | 1.35E-07 | positive regulation of ovulation | GO:0060279 | |||
| 4:79,364,290–79,364,421 | 0.223 | 1.30E-05 | |||||
| 4:79,410,632–79,410,649 | 0.433 | 3.46E-09 | |||||
| 4:79,467,732–79,468,003 | 0.286 | 0.000264 | |||||
| 4:79,470,908–79,471,096 | 0.324 | 8.99E-07 | |||||
| 4:79,511,040–79,511,072 | −0.227 | 0.00129 | |||||
| 4:79,522,334–79,522,542 | 0.553 | 1.75E-12 | |||||
| 4:79,524,739–79,524,926 | 0.346 | 1.16E-08 | |||||
| 4:79,544,088–79,544,103 | −0.309 | 1.46E-09 | |||||
| 4:79,554,774–79,554,784 | 0.334 | 4.59E-06 | |||||
| 4:79,568,886–79,568,895 | 0.545 | 1.61E-08 | |||||
| 4:79,580,604–79,580,858 | 0.643 | 6.50E-17 | |||||
| 4:79,581,799–79,582,035 | 0.507 | 6.30E-12 | |||||
| 4:79,595,470–79,595,497 | 0.625 | 1.59E-15 | |||||
| 4:79,601,022–79,601,037 | −0.129 | 9.26E-06 | |||||
| 4:79,605,844–79,606,024 | 0.465 | 5.60E-14 | |||||
| 4:79,658,524–79,658,656 | −0.28 | 0.000333 | |||||
| 4:79,658,703–79,658,930 | 0.206 | 0.000186 | |||||
| 4:79,794,804–79,794,808 | 0.385 | 1.32E-09 | |||||
| 4:79,818,557–79,818,672 | 0.266 | 6.96E-09 | |||||
| 4:79,821,799–79,821,883 | 0.403 | 7.91E-08 | |||||
| 4:79,823,656–79,823,864 | 0.47 | 1.76E-08 | |||||
| 4:79,829,698–79,829,729 | −0.222 | 0.0017 | |||||
| 4:79,836,260–79,836,367 | 0.56 | 5.75E-09 | |||||
| 4:79,968,621–79,968,690 | −0.37 | 1.87E-09 | |||||
| 4:80,049,783–80,050,296 | −0.254 | 4.52E-14 | |||||
| 4:80,063,788–80,063,855 | −0.244 | 1.31E-06 | |||||
| 4:80,085,854–80,085,996 | −0.223 | 4.88E-05 | |||||
| 4:80,150,315–80,150,500 | 0.274 | 2.37E-06 | |||||
| 4:80,157,514–80,157,656 | 0.475 | 6.14E-13 | |||||
| JUP | 11(41441802–41,442,083) | −0.22 | 0.000192 | oocyte development | GO:0048599 | ||
| 11(41458174–41,458,384) | 0.254 | 8.93E-07 | |||||
chr chromosome, DMR different methylated regions, meth diff the difference in methylation levels between HP and LP (LP vs HP); a positive number means the methylation levels of this region in the HP group are higher than those in the LP group, and a negative number means that the methylation levels of this region in the HP group are lower than those in the LP group, GO pathway The name of the GO term, GO ID The ID of the GO term, KEGG pathway The name of the KEGG pathway, KO ID The ID of the KEGG pathway